Journals / Retina-Vitreus / 2018 / Cilt: 27 - Sayı: 1

Effi cacy of Intravitreal Afl ibercept as a First Line Therapy in Macular Telengiectasia Type 1

Tip 1 Maküler Telenjiektazili Olguda İlk Seçenek Tedavi Olarak İntravitreal Afl iberceptin Etkinliği

Pages
82–85
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This case study suggests that intravitreal afl ibercept injection may bean effective therapy for the treatment of macular edema due to type 1 MACTEL.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:We present a 66 year old male patient who was admitted to our clinic with blurred vision in the right eye, which commenced 6 monthsprior.
📊
Key Findings & Data:Ophthalmic examination of the patient revealed type 1 macular telangiectasia (MACTEL).
💡
Conclusion & Impact:This case study suggests that intravitreal afl ibercept injection may bean effective therapy for the treatment of macular edema due to type 1 MACTEL.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

We present a 66 year old male patient who was admitted to our clinic with blurred vision in the right eye, which commenced 6 monthsprior. Ophthalmic examination of the patient revealed type 1 macular telangiectasia (MACTEL). As a fi rst line therapy, two occasionsof intravitreal afl ibercepts were administered a month apart. For the fi rst and second post-treatment examinations, visual acuity was 0.7and 1.0 while the thickness of the macula was measured at 295 μm and 254 μm, respectively. At the 12th month post-treatment, visualacuity was stabilized and sub-intra retinal fl uid was not detected. This case study suggests that intravitreal afl ibercept injection may bean effective therapy for the treatment of macular edema due to type 1 MACTEL.

Özet

66 yaşında erkek hasta 6 ay önce başlayan bulanık görme ve görme azlığı şikayetleri ile kliniğimize başvurdu. Oftalmoljik değerlen- dirme sonrası Tip 1 maküler telenjiektazi tanısı konan olguya ilk seçenek tedavi olarak birer ay ara ile 2 kez intravitreal afl ibercept enjeksiyonu uygulandı. Enjeksiyon sonrası vizitlerde görme keskinliği snellen eşeli ile 0.4 düzeyinden sırasıyla 0.7 ve 1.0 düzeyine yükselirken makula kalınlığı 425 μm’den sırasıyla 295 μm ve 254 μm’ye geriledi. Tedavi sonrası 12. ay kontrolünde görme keskin- liğinin stabil olduğu gözlendi. İntraretinal ve subretinal sıvı izlenmedi. Olgumuz, tip 1 maküler telenjiektaziye bağlı makula ödemi olgularında intravitreal afl ibercept tedavisinin etkili bir yöntem olabileceğini göstermektedir.

🔖

Cite This Article

KOÇAK, N. (2022). Effi cacy of Intravitreal Afl ibercept as a First Line Therapy in Macular Telengiectasia Type 1. Retina-Vitreus, Cilt: 27 - Sayı: 1, 82–85. https://ajindex.com/articles/589123

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Yannuzzi LA, Bardal AMC, Freund KB et al. Idiopathic macular telangiectasia. Archives of Ophthalmology. 2006;124:450–460. Gass JD and Oyakawa RT. Idiopathic juxtafoveolar retinal telangi- ectasis. Archives of Ophthalmology. 1982;100:769–780.
  2. Kotoula MG, Chatzoulis DZ, Karabatsas Ch et al. Resolution of macular edema in idiopathic juxtafoveal telangiectasis using PDT. Ophthalmic Surgery Lasers and Imaging. 2009;40:65–67.
  3. Gamulescu MA, Walter A, Sachs H et al. Bevacizumab in the treatment of idiopathic macular telangiectasia. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2008;246:1189– 1193. Takayama K, Ooto S, Tamura H et al. Intravitreal bevacizumab for type 1 idiopathic macular telangiectasia. Eye. 2010;24:1492–1497.
  4. Koay CL, Chew FLM, and Visvaraja S. Bevacizumab and type 1 idiopathic macular telangiectasia. Eye. 2011;25:1663–1665. O’Sam S, Vaze A, Gillies M et al. Macular Oedema in Idiopathic Macular Telangiectasia Type 1 Responsive to Afl ibercept but Not Bevacizumab. Case Rep Ophthalmol Med. 2014:1-4.
  5. Ciarnella A, Verrilli S, Fenicia V et al. Intravitreal ranibizumab and laser photocoagulation in the management of idiopathic jux- tafoveolar retinal telangiectasia type 1: a case report. Case Rep Ophthalmol. 2012;3:298–303.
  6. Rouvas A, Malamos P, Douvali M et al. Twelve months of fol- low-up after intravitreal injection of ranibizumab for the treat- ment of idiopathic parafoveal telangiectasia. Clin Ophthalmol. 2013;7:1357–1362.
  7. Kovach JL, Hess H, Rosenfeld PJ. Macular Telangiectasia Type 1 Managed With Long-Term Afl ibercept Therapy. Ophthalmic Surg Lasers Imaging Retina. 2016;47:593-595.
  8. Okamoto N, Tobe T, Hackett SF et al. Transgenic mice with in- creased expression of vascular endothelial growth factor in the ret- ina: a new model of intraretinal and subretinal neovascularization. Am J Pathol. 1997;151:281–291.
  9. Autiero M, Waltenberger J, Communi D et al. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med. 2003;9:936–943.
  10. He K, Cui B, Li G et al. The effect of anti-VEGF drugs (bevaci- zumab and afl ibercept) on the survival of patients with metastatic colorectal cancer (mCRC). OncoTargets and Therapy. 2012;5:59– 65.